Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

Autor: Sara Agraso, Martin Lázaro, Xose Luis Firvida, Lucía Santomé, Natalia Fernández, Cristina Azpitarte, Luis Leon, Carme Garcia, Gerardo Hudobro, Ma Carmen Areses, Begoña Campos, Nazaret Quiroga, Jorge García, Joaquín Casal
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100646- (2022)
Druh dokumentu: article
ISSN: 2468-2942
DOI: 10.1016/j.ctarc.2022.100646
Popis: Background: In clinical studies, first-line afatinib demonstrated efficacy in Del19-EGFR NSCLC. Materials and Methods: This prospective, non-interventional study assessed efficacy and safety of first-line afatinib in patients with advanced/metastatic NSCLC with Del19-EGFR from Galicia (Spain), with a preplanned analysis by age ( 70 years) benefitted from afatinib as much as younger patients. The safety profile of afatinib was as expected, albeit more dose reductions in older patients. Afatinib may be an option for patients with Del19 EGFR NSCLC, even in those who are older.
Databáze: Directory of Open Access Journals
Externí odkaz: